Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy

Journal of Medical Virology

Volumn 70, Issue 4, 2003, Pages 588-593

  Schvoerer, E ^a   Navas, M C ^a   Thumann, C ^a   Fuchs, A ^a   Meyer, N ^b   Habersetzer, F ^c   Stoll Keller, F ^a  

^a INSERM   (France)

^b HÔPITAL CIVIL   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Hepatitis C virus; Interleukin 12; Interleukin 18

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 12; INTERLEUKIN 18; LIPOPOLYSACCHARIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; VIRUS GENOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CELLS, CULTURED; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-18; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

HEPATITIS C VIRUS;

EID: 0038046075     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10434     Document Type: Article

References (41)

1. Akira S. 2000. The role of IL-18 in innate immunity. Curr Opin Immunol 12:59-63.
2. Amaraa R, Mareckova H, Urbanek P, Fucikova T. 2002. Production of interleukins 10 and 12 by activated peripheral blood monocytes/macrophages in patients suffering from chronic hepatitis C virus infection with respect to the response to interferon and ribavirin treatment. Immunol Lett 83:209-214.
3. Antonaci S, Piazzolla G, Napoli N, Vella FS, Fiore G, Schiraldi O. 2001. Relationship between T lymphocyte responsiveness and T-helper1/T-helper2 type cytokine release in chronic hepatitis C: a critical reappraisal. Microbios 106:203-212.
4. Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. 1992. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells ofinfected patients. J Infect Dis 166:1276-1280.
5. Boyer N, Marcellin P. 2000. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 32:98-112.
6. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. 1996. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alpha. Hepatology 24:6-9.
7. Christie JML, Chapel H, Chapman RW, Rosenberg WMC. 1999. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology 30:1037-1044.
8. Cribier B, Schmitt C, Rey D, Lang JM, Kirn A, Stoll-Keller F. 1998. Production of cytokines in patients infected by hepatitis C virus. J Med Virol 55:89-91.
9. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, Mühl H, Yoon DY, Reznikov LL, Kim SH, Rubinstein M. 1998. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 63:658-664.
10. Dunham SP, Flynn JN, Rigby MA, Macdonald J, Bruce J, Cannon C, Golder MC, Hanlon L, Harbour DA, Mackay NA, Spibey N, Jarrett O, Neil JC. 2002. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine 20:1483-1496.
11. Fan XG, Tang FQ, Yi H, Liu WE, Houghton M, Hu GL. 2000. Effect of IL-12 on T-cell immune responses in patients with chronic HCV infection. APMIS 108:531-538.
12. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. 2001. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 22:556-560.
13. Fujioka N, Akazawa R, Ohashi K, Fujii M, Ikeda M, Kurimoto M. 1999. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol 73:2401-2409.
14. Hempel G, Galle PR, Löhr HF. 2001. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C. J Med Virol 64:340-349.
15. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 21:632-638.
16. Ishii K, Takamura N, Shinohara E, Shin HY, Ikehara T, Hata S, Kawafune T, Sumino Y, Ohmoto Y. 2002. Intracellular cytokine analysis of CD4-positive T cells predictive of sustained response to interferon therapy for patients with chronic hepatitis C. Dig Dis Sci 47:778-783.
17. Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. 1997. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 108:138-143.
18. Kakumu S, Ito S, Tetsuya I, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K. 2000. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 15:431-436.
19. Kaser A, Novick D, Rubinstein M, Siegmund B, Enrich B, Koch RO, Vogel W, Kim SH, Dinarello CA, Tilg H. 2002. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 129:332-338.
20. Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerbruch T, Spengler U. 1999. Increased frequency of the HLADR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 29:337-343.
21. Lee JH, Teuber G, von Wagner M, Roth WK, Zeuzem S. 2000. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. J Med Virol 60:264-268.
22. Lerat H, Inchauspé G. 1997. Tropisme extrahépatique du virus de l'hépatite C. Virologie 1:291-300.
23. McGuinness PH, Painter D, Davies S, McCaughan GW. 2000. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46:260-269.
24. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
25. Munder M, Mallo M, Eichmann K, Modolell M. 1998. Murine macrophages secrete interferon-gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 187:2103-2108.
26. Munder M, Mallo M, Eichmann K, Modolell M. 2001. Direct stimulation of macrophages by IL-12 and IL-18 - a bridge built on solid ground. Immunol Lett 75:159-160.
27. Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, JacobsonBrown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P. 2001. Cytokines as predictors for sustained response and as marker for immunomodulation in patients with chronic hepatitis C. Clin Biochem 34:173-182.
28. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182:28-35.
29. Osna N, Silonova G, Vilgert N, Hagina E, Kuse V, Giaidraitis V, Zvirbliene A, Mauricas M, Sochnev A. 1997. Chronic hepatitis C: T-helper1/T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest 57:703-710.
30. Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S. 2001. Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C. J Interferon Cytokine Res 21:453-461.
31. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825-832.
32. Quiroga JA, Martin J, Navas S, Carreño V. 1998. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 178:247-251.
33. Sarih M, Bouchrit N, Benslimane A. 2000. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol Lett 74:117-120.
34. SeeffLB. 1997. Natural history of hepatitis C. Hepatology 26:21S-28S.
35. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 163:6236-6243.
36. Sugwara I. 2000. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect 2:1257-1263.
37. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578-582.
38. Teuber G, Rossol S, Lee JH, Dietrich CF, Zeuzem S. 2002. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment. Z Gastroenterol 40:487-495.
39. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. 1997. Detection of type 2-like T-helper cells in hepatitis C virus infection implications for hepatitis C virus chronicity. Hepatology 25:449-458.
40. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, Spengler U. 2002. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol 8:562-566.
41. Zhang Y, Wang Y, Gilmore X, Xu K, Mbawuike IN. 2001. Independent and synergistic effects of interleukin-18 and interleukin-12 in augmenting cytotoxic T lymphocyte responses and IFN-gamma production in aging. J Interferon Cytokine Res 21:843-850.